File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.phymed.2018.10.003
- Scopus: eid_2-s2.0-85056214548
- PMID: 30668331
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer
Title | Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer |
---|---|
Authors | |
Keywords | Breast cancer Cistanche deserticola Dioscorea opposita Estrogen receptor Estrogenic herbs Safety |
Issue Date | 2019 |
Citation | Phytomedicine, 2019, v. 56, p. 103-117 How to Cite? |
Abstract | Background: An increasing number of breast cancer patients in Asian countries has been found to consume dietary supplements including phytoestrogen-rich Chinese herbal medicines with an expectation to alleviate the side effects of conventional cancer therapies. Purpose: The question of whether estrogenic Chinese herbal medicines are beneficial or detrimental to the health of breast cancer patients remains uncertain. Study Design: The present study aimed at establishing a systematic approach to look at the safety profiles of estrogenic Chinese herbal medicines (CHM). Methods: The effects of estrogenic CHM on the growth of human breast cancer cells as well as the progression of breast tumors in mice have been investigated. Results: Our results demonstrated that among 10 selected estrogenic CHM, the aqueous extracts of Cistanche deserticola (CD) and Dioscorea opposita (DO) at 0.4 to 1.6 mg/ml significantly stimulated cell viability in both estrogen receptor (ER)-positive (MDA-MB-361 and MCF-7) and ER-negative (SKBR3 and MDA-MB-231) breast cancer cells. However, results from animal studies showed that no significant difference was found on the size of mouse 4T1 breast tumors in CD- and DO-treated mice when compared with the control group, while the number of proliferative cells were found to be increased in DO-treated group. Besides, CD and DO treatments induced significant immunomodulatory effects on 4T1 tumor-bearing mice by increasing the production of cytokines IL-2 and IFN-γ and modulation of regulatory T-cells. Furthermore, CD and DO treatments did not stimulate, but in fact suppressed human triple-negative MDA-MB-231 breast xenografts growth in immunodeficiency mice. Conclusion: The considerable concerns on the use of CD and DO in breast cancer patients could be relieved to some extents upon the findings of this pre-clinical study. The potential harmful effects of estrogenic Chinese herbal medicines on breast cancer growth should be verified in both cell-based and tumor-bearing mice models. |
Persistent Identifier | http://hdl.handle.net/10722/343271 |
ISSN | 2023 Impact Factor: 6.7 2023 SCImago Journal Rankings: 1.267 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yue, Grace Gar Lee | - |
dc.contributor.author | Wong, Lok Sze | - |
dc.contributor.author | Leung, Hoi Wing | - |
dc.contributor.author | Gao, Si | - |
dc.contributor.author | Tsang, Julia Yuen Shan | - |
dc.contributor.author | Lin, Zhi Xiu | - |
dc.contributor.author | Tse, Gary Man Kit | - |
dc.contributor.author | Lau, Clara Bik San | - |
dc.date.accessioned | 2024-05-10T09:06:48Z | - |
dc.date.available | 2024-05-10T09:06:48Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Phytomedicine, 2019, v. 56, p. 103-117 | - |
dc.identifier.issn | 0944-7113 | - |
dc.identifier.uri | http://hdl.handle.net/10722/343271 | - |
dc.description.abstract | Background: An increasing number of breast cancer patients in Asian countries has been found to consume dietary supplements including phytoestrogen-rich Chinese herbal medicines with an expectation to alleviate the side effects of conventional cancer therapies. Purpose: The question of whether estrogenic Chinese herbal medicines are beneficial or detrimental to the health of breast cancer patients remains uncertain. Study Design: The present study aimed at establishing a systematic approach to look at the safety profiles of estrogenic Chinese herbal medicines (CHM). Methods: The effects of estrogenic CHM on the growth of human breast cancer cells as well as the progression of breast tumors in mice have been investigated. Results: Our results demonstrated that among 10 selected estrogenic CHM, the aqueous extracts of Cistanche deserticola (CD) and Dioscorea opposita (DO) at 0.4 to 1.6 mg/ml significantly stimulated cell viability in both estrogen receptor (ER)-positive (MDA-MB-361 and MCF-7) and ER-negative (SKBR3 and MDA-MB-231) breast cancer cells. However, results from animal studies showed that no significant difference was found on the size of mouse 4T1 breast tumors in CD- and DO-treated mice when compared with the control group, while the number of proliferative cells were found to be increased in DO-treated group. Besides, CD and DO treatments induced significant immunomodulatory effects on 4T1 tumor-bearing mice by increasing the production of cytokines IL-2 and IFN-γ and modulation of regulatory T-cells. Furthermore, CD and DO treatments did not stimulate, but in fact suppressed human triple-negative MDA-MB-231 breast xenografts growth in immunodeficiency mice. Conclusion: The considerable concerns on the use of CD and DO in breast cancer patients could be relieved to some extents upon the findings of this pre-clinical study. The potential harmful effects of estrogenic Chinese herbal medicines on breast cancer growth should be verified in both cell-based and tumor-bearing mice models. | - |
dc.language | eng | - |
dc.relation.ispartof | Phytomedicine | - |
dc.subject | Breast cancer | - |
dc.subject | Cistanche deserticola | - |
dc.subject | Dioscorea opposita | - |
dc.subject | Estrogen receptor | - |
dc.subject | Estrogenic herbs | - |
dc.subject | Safety | - |
dc.title | Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.phymed.2018.10.003 | - |
dc.identifier.pmid | 30668331 | - |
dc.identifier.scopus | eid_2-s2.0-85056214548 | - |
dc.identifier.volume | 56 | - |
dc.identifier.spage | 103 | - |
dc.identifier.epage | 117 | - |
dc.identifier.eissn | 1618-095X | - |